Zum Inhalt

HealthOSArzneimittel

HealthOSEvidence Desk

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (19)

Gegenanzeigen · Norvir

Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 5

HOS-086159 · Präparat HOS-083284

Microsomal Lomitapide Increased plasma concentrations of lomitapide triglyceride transfer (see section 4.5). protein (MTTP) inhibitor PDE5 inhibitors Avanafil Increased plasma concentrations of avanafil (see section 4.4. and 4.5). Sildenafil Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only. Increased plasma concentrations of sildenafil. Thereby, increasing the potential for sildenafil- associated adverse events (which include hypotension and syncope). See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction. Vardenafil Increased plasma concentrations of vardenafil (see section 4.4. and 4.5). Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate, estazolam, flurazepam, diazepam, estazolam, flurazepam, oral oral midazolam and midazolam and triazolam. Thereby, increasing triazolam the risk of extreme sedation and respiratory depression from these agents. (For caution on parenterally administered midazolam, see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) lomitapide (HOS-086160) clorazepate (HOS-086164) diazepam (HOS-085904) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) flurazepam (HOS-086166) midazolam (HOS-086167) vardenafil (HOS-086163)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 08cb4669d26fd4170f47a5f99fcf18bde7e922c35f378d07e3e1c1cab8b82945 · Zeichen 6375–8447 im Abschnitt

Gegenanzeigen · Norvir

Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 37

HOS-086390 · Präparat HOS-083284

Microsomal Lomitapide Increased plasma concentrations of lomitapide triglyceride transfer (see section 4.5). protein (MTTP) inhibitor PDE5 inhibitor Avanafil Increased plasma concentrations of avanafil (see section 4.4. and 4.5). Sildenafil Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only. Increased plasma concentrations of sildenafil. Thereby, increasing the potential for sildenafil- associated adverse events (which include hypotension and syncope). See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction. Vardenafil Increased plasma concentrations of vardenafil (see section 4.4. and 4.5). Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate, estazolam, flurazepam, diazepam, estazolam, flurazepam, oral oral midazolam and midazolam and triazolam. Thereby, increasing triazolam the risk of extreme sedation and respiratory depression from these agents. (For caution on parenterally administered midazolam, see section 4.5.). Ritonavir medicinal product level decreased Herbal Preparation St. John’s Wort Herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of ritonavir (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) lomitapide (HOS-086160) clorazepate (HOS-086164) diazepam (HOS-085904) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) flurazepam (HOS-086166) midazolam (HOS-086167) vardenafil (HOS-086163)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 235db82cd2afd722d3066659d7d625c3a96a3162e89ca0b2b4a6f83e7ca9d95d · Zeichen 6173–8675 im Abschnitt

Wechselwirkungen · Norvir

Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 21–22

HOS-086320 · Präparat HOS-083284

21 Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products Co-administered Medicinal Products Dose of Co- Dose of Effect on Co- Effect on Co- administered NORVIR (mg) administered administered Medicinal Products Medicinal Medicinal Products (mg) Products Cmax AUC Triazolam 0.125, single dose 200, 4 doses ↑ > 20 fold ↑ 87% Ritonavir co-administration is likely to result in increased plasma concentrations of triazolam and is therefore contraindicated (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triazolam (HOS-086168)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 039161a22dea2643b1fdec1594d7bd3d6e92739bb7c122ff67c4c52cb2415c31 · Zeichen 51558–52533 im Abschnitt

Wechselwirkungen · Norvir

Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54

HOS-086483 · Präparat HOS-083284

Triazolam 0.125, single dose 200, 4 ↑ > 20 fold ↑ 87% doses Ritonavir co-administration is likely to result in increased plasma concentrations of triazolam and is therefore contraindicated (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triazolam (HOS-086168)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9a5a169f2949c39b0a7142f7f1513bc21f456cb65604ae49b2e8505a7b1f7c5f · Zeichen 53527–53953 im Abschnitt

Gegenanzeigen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 6

HOS-108817 · Präparat HOS-093083

HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of Inhibitors lovastatin and simvastatin; thereby, increasing the risk of myopathy including rhabdomyolysis (see section 4.5). Microsomal Lomitapide Increased plasma concentrations of triglyceride transfer lomitapide (see section 4.5). protein (MTTP) inhibitor Phosphodiesterase Avanafil Increased plasma concentrations of (PDE5) inhibitors avanafil (see sections 4.4 and 4.5). Sildenafil Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only. Increased plasma concentrations of sildenafil. Thereby, increasing the potential for sildenafil-associated adverse events (which include hypotension and syncope). See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction. Vardenafil Increased plasma concentrations of vardenafil (see sections 4.4 and 4.5) Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral midazolam and triazolam. Thereby, increasing the risk of extreme sedation and respiratory depression from these agents. For caution on parenterally administered midazolam, see section 4.5. Lopinavir/ritonavir medicinal product level decreased Herbal products St. John’s wort Herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of lopinavir and ritonavir (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c938be9b188cbabde88400ddb49de67c2831b955f638dc8fa5306b13f1652968 · Zeichen 6187–9289 im Abschnitt

Gegenanzeigen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 43–44

HOS-108990 · Präparat HOS-093083

43 Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral midazolam and triazolam. Thereby, increasing the risk of extreme sedation and respiratory depression from these agents. For caution on parenterally administered midazolam, see section 4.5. Lopinavir/ritonavir medicinal product level decreased Herbal products St. John’s wort Herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of lopinavir and ritonavir (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triazolam (HOS-086168) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 92a02386fc1a77aef711a4b1e6d441f26b16e78482f67469b16622696dc32d8d · Zeichen 8625–9989 im Abschnitt

Gegenanzeigen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 78–79

HOS-109064 · Präparat HOS-093083

78 Phosphodiesterase Avanafil Increased plasma concentrations of (PDE5) inhibitors avanafil (see sections 4.4 and 4.5) Sildenafil Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only. Increased plasma concentrations of sildenafil. Thereby, increasing the potential for sildenafil-associated adverse events (which include hypotension and syncope). See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction. Vardenafil Increased plasma concentrations of vardenafil (see sections 4.4 and 4.5) Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral midazolam and triazolam. Thereby, increasing the risk of extreme sedation and respiratory depression from these agents. For caution on parenterally administered midazolam, see section 4.5. Lopinavir/ritonavir medicinal product level decreased Herbal products St. John’s wort Herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of lopinavir and ritonavir (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 5fd5fb90c510eab32eaadc8b17bd2236491bc4b4553317338a4ddfd4a5d22f67 · Zeichen 7137–9814 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24

HOS-112118 · Präparat HOS-093615

The mechanism of interaction is CYP3A4 and UGT1A1 inhibition. Concentrations of atazanavir (when given with ritonavir) were not significantly affected. Methadone, stable maintenance No significant effect on methadone No dosage adjustment is necessary dose concentrations was observed. Given that if methadone is co-administered (atazanavir 400 mg once daily) low dose ritonavir (100 mg twice daily) with REYATAZ. has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co- administered with REYATAZ, based on these data. PULMONARY ARTERIAL HYPERTENSION PDE5 Inhibitors Sildenafil Co-administration with REYATAZ may A safe and effective dose in result in increased concentrations of the combination with REYATAZ has PDE5 inhibitor and an increase in PDE5- not been established for sildenafil inhibitor-associated adverse events. when used to treat pulmonary arterial hypertension. Sildenafil, The mechanism of interaction is CYP3A4 when used for the treatment of inhibition by atazanavir and/or ritonavir. pulmonary arterial hypertension, is contraindicated (see section 4.3). SEDATIVES Benzodiazepines Midazolam Midazolam and triazolam are extensively Co-administration of REYATAZ Triazolam metabolised by CYP3A4. Co- with triazolam or orally administration with REYATAZ may cause administered midazolam is a large increase in the concentration of contraindicated (see section 4.3), these benzodiazepines. No drug interaction whereas caution should be used study has been performed for the co- with co-administration of administration of REYATAZ with REYATAZ and parenteral benzodiazepines. Based on data for other midazolam. If REYATAZ is co- CYP3A4 inhibitors, plasma concentrations administered with parenteral of midazolam are expected to be midazolam, it should be done in an significantly higher when midazolam is intensive care unit (ICU) or similar given orally. Data from concomitant use of setting which ensures close clinical parenteral midazolam with other protease monitoring and appropriate medical inhibitors suggest a possible 3-4-fold management in case of respiratory increase in midazolam plasma levels. depression and/or prolonged sedation. Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) protease (HOS-085623) sildenafil (HOS-086162) ritonavir (HOS-084521) triazolam (HOS-086168) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage be486e27c0486d810d40c1b37da9b7f69c7a35ad1fcade19cc1e1d57a1b71724 · Zeichen 71400–75434 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 44

HOS-112157 · Präparat HOS-093615

Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally administered midazolam, lomitapide, and ergot alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). Co-administration of REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed-dose combination is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with increased grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma concentrations (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) cisapride (HOS-085610) pibrentasvir (HOS-086298) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) glecaprevir (HOS-086297) grazoprevir (HOS-108815) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) terfenadine (HOS-085607) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8c472f02d161fbf877b321685a02acd6721db094612098433562a9a244834b35 · Zeichen 315–1385 im Abschnitt

Gegenanzeigen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4

HOS-114797 · Präparat HOS-094169

Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone, bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics (such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition, co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and metoprolol given in heart failure (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) propafenone (HOS-084530) cisapride (HOS-085610) lovastatin (HOS-086157) flecainide (HOS-086203) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) metoprolol (HOS-090094) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 21

HOS-114847 · Präparat HOS-094169

Ritonavir is a potent inhibitor of CYP3A4 and therefore affect drugs metabolised by this enzyme. Triazolam Based on theoretical The concomitant use of Aptivus, No interaction study considerations, tipranavir, co- co-administered with low dose performed administered with low dose ritonavir, with triazolam is ritonavir, is expected to increase contraindicated due to potential triazolam concentrations. serious and/or life threatening events (see section 4.3) Inhibition of CYP 3A4 by tipranavir/r Nucleoside analogue DNA polymerase inhibitors Valaciclovir 500 mg Co-administration of valaciclovir, Valaciclovir and Aptivus with single dose tipranavir and low dose ritonavir low dose ritonavir, may be co- was not associated with clinically administered without dose relevant pharmacokinetic effects. adjustment.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) triazolam (HOS-086168)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 3c13933b82e9d5525c7497a8850fd2994f8074388a1acf5b4ea9c30dcbbedae6 · Zeichen 55229–56473 im Abschnitt

Gegenanzeigen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6

HOS-116288 · Präparat HOS-094447

Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that are highly dependent on CYP3A for clearance, which results in increased exposure to the co-administered medicinal product. Therefore, concomitant treatment with such medicinal products for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active substances include e.g.: - alfuzosin - amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine - astemizole, terfenadine - colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - elbasvir/grazoprevir - cisapride - dapoxetine - domperidone - naloxegol - lurasidone, pimozide, quetiapine, sertindole (see section 4.5) - triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5) - sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil - simvastatin, lovastatin, lomitapide (see section 4.5) - ticagrelor (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) cobicistat (HOS-088111) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt

Gegenanzeigen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49

HOS-116497 · Präparat HOS-094447

Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These active substances include e.g.: - alfuzosin - amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine - astemizole, terfenadine - colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - elbasvir/grazoprevir - cisapride - dapoxetine - domperidone - naloxegol - lurasidone, pimozide, quetiapine, sertindole (see section 4.5) - triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5) - sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil - simvastatin, lovastatin and lomitapide (see section 4.5) - ticagrelor (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 66

HOS-116534 · Präparat HOS-094447

Midazolam (oral) PREZISTA with low dose Triazolam ritonavir with triazolam or oral midazolam is contraindicated (see section 4.3). TREATMENT FOR PREMATURE EJACULATION Dapoxetine Not studied. Co-administration of boosted PREZISTA with dapoxetine is contraindicated.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) triazolam (HOS-086168) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9eb1d9b5669a143cfca8162f42cd6e1f1282d6f69be48456de0fe46b1cff9165 · Zeichen 68983–69712 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 106

HOS-116623 · Präparat HOS-094447

Midazolam (oral) Boosted PREZISTA with Triazolam triazolam or oral midazolam is contraindicated (see section 4.3). TREATMENT FOR PREMATURE EJACULATION Dapoxetine Not studied. Co-administration of boosted PREZISTA with dapoxetine is contraindicated. UROLOGICAL DRUGS Fesoterodine Not studied. Use with caution. Monitor for Solifenacin fesoterodine or solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin may be necessary. # Studies have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). † The efficacy and safety of the use of PREZISTA with 100 mg ritonavir and any other HIV PI (e.g. (fos)amprenavir and tipranavir) has not been established in HIV patients. According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. ‡ Study was conducted with tenofovir disoproxil fumarate 300 mg once daily.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): solifenacin (HOS-116433) protease (HOS-085623) amprenavir (HOS-086183) fesoterodine (HOS-116432) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) triazolam (HOS-086168) tipranavir (HOS-086184) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 14ad7ec122e17b6bf0a9b5a35c80cb2b9d577809d7de8d4ecda9d9afbe9bbd5b · Zeichen 77338–79172 im Abschnitt

Gegenanzeigen · Ketoconazole Esteve (previously Ketoconazole HRA)

Ketoconazole Esteve 200 mg tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-132828 · Präparat HOS-097310

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1; - Hypersensitivity to any imidazole antifungal medicinal product; - Acute or chronic liver disease and/or if pre-treatment liver enzymes levels are above 2 times the upper limit of normal (see sections 4.2 and 4.4): - Pregnancy (see section 4.6); - Breastfeeding (see section 4.6); - Congenital or documented acquired QTc prolongation ; - Concomitant therapy with any of the following medicinal products which may interact and result in potentially life-threatening adverse reactions (see section 4.5): o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin) due to an increased risk of skeletal muscle toxicity including rhabdomyolysis; o eplerenone due to an increased risk of hyperkalemia and hypotension; o substances that may have their plasma concentrations increased and have QT prolonging potential: methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir 1000/100 mg bid), ranolazine, mizolastine, halofantrine; o dabigatran due to an increased bleeding risk; o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and respiratory depression; o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse reactions; o lurasidone; o quetiapine due to an increased risk of toxicity; o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of hepatotoxicity and QT interval prolongation; o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) ergot alkaloids (HOS-108807) imidazole (HOS-117862) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) ergotamine (HOS-086154) ritonavir (HOS-084521) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage f9d16641f2e5b06b321fa0c79f0dacdfede818d20585398b4d37ddb19dad6a14 · Zeichen 0–2044 im Abschnitt

Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)

Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132842 · Präparat HOS-097310

o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin) due to an increased risk of skeletal muscle toxicity including rhabdomyolysis; o eplerenone due to an increased risk of hyperkalemia and hypotension; o substances that may have their plasma concentrations increased and have QT prolonging potential : methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir 1000/100 mg bid), ranolazine, mizolastine, halofantrine; o dabigatran due to an increased bleeding risk; o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and respiratory depression; o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse reactionsevents o lurasidone; o quetiapine due to an increased risk of toxicity; o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of hepatotoxicity and QT interval prolongation; o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure; o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions; o irinotecan due to an alteration of the metabolism of this medicinal product; o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of these medicinal products; o vardenafil in men older than 75-years due to increased risk of adverse reactions o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions; o fesoterodine and solifenacin in patients with renal impairment; o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone secretion”.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) solifenacin (HOS-116433) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) ombitasvir (HOS-110300) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) colchicine (HOS-086147) everolimus (HOS-086310) fesoterodine (HOS-116432) sirolimus (HOS-085172) ergotamine (HOS-086154) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) ranolazine (HOS-086141) irinotecan (HOS-112102) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609) vardenafil (HOS-086163)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 0b65d259964c6f340994be44a864bad55b31283e3fc412d0d5a47323a792d889 · Zeichen 171–2105 im Abschnitt

Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)

Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-132861 · Präparat HOS-097310

Monitoring of QT-prolongation if used concomitantly. Bortezomib Bortezomib: Careful monitoring. Busulfan AUC: ↑ 1.4-fold Dose adjustment of each medicinal Docetaxel Imatinib: product may be required. Imatinib AUC: ↑ 1.4-fold Cabazitaxel Cmax: ↑ 1.3-fold ↑in plasma concentrations of docetaxel have been observed Potential ↑in plasma concentrations of busulfan Cabazitaxel AUC: ↑ 1.3-fold Paclitaxel Paclitaxel: Careful monitoring. No change in plasma concentration were Dose adjustment of paclitaxel shown with paclitaxel concentrate. No may be required. studies were performed with albumin bound nanoparticules. Vincristine, vinblastine Potential ↑in plasma concentrations of Careful monitoring as it may cause (vinca alkaloids) vinca alkaloids. an earlier onset and/or an increased severity of side-effects. Antipsychotics, Anxiolytics and Hypnotics Triazolam AUC: ↑ have been observed Contraindicated due to the risk of Alprazolam Cmax: ↑ have been observed potentially prolonged or increased Midazolam oral sedation and respiratory depression (see section 4.3). Lurasidone Lurasidone: Contraindicated due to the increased AUC: ↑ 9 fold risk of adverse reactions (see section Cmax: ↑ 6 fold 4.3). Pimozide Potential ↑in plasma concentrations of Contraindicated due to the risk of pimozide. serious cardiovascular events including QT prolongation (see section 4.3). Sertindole Potential ↑in plasma concentrations of Contraindicated due to the risk of QT sertindole. prolongation (see section 4.3). Quetiapine Quetiapine: Contraindicated as it may increase AUC: ↑ 6.2-fold quetiapine-related toxicity (see Cmax: ↑ 3.4-fold section 4.3). Haloperidol Potential ↑in plasma concentrations of Not recommended due to the haloperidol. increased risk of QT prolongation and extrapyramidal symptoms. It may be necessary to reduce haloperidol dosage. Reboxetine Reboxetine: Not recommended because of AUC: ↑ 1.5-fold of both enantiomers reboxetine narrow’s therapeutic margin. Midazolam IV Midazolam: Careful monitoring. AUC: ↑ 1.6-fold Dose adjustment of midazolam IV may be required. 11 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration Buspirone Potential ↑in plasma concentrations of Careful monitoring. buspirone. Dose adjustement of buspirone may be required. Aripiprazole Aripiprazole Careful monitoring. AUC: ↑ 1.6-fold Aripiprazole dose should be reduced Cmax: ↑ 1.4-fold to approximatively one-half of its prescribed dose. Risperidone Potential ↑in AUC of risperidone: Careful monitoring. Dose adjustment of risperidone may be required. Antivirals products Saquinavir Saquinavir: Contraindicated due to the risk of QT (saquinavir/ritonavir AUC: ↔ prolongation (see section 4.3). 1000/100 mg bid) Cmax: ↔ Ketoconazole AUC: ↑ 2.7-fold Cmax:↑ 1.5-fold (CYP3A4 enzyme inhibition by ritonavir) Paritaprevir: Contraindicated due to the increased AUC: ↑2.2-fold risk of adverse reactions (see section Cmax: ↑1.7-fold 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aripiprazole (HOS-129408) sertindole (HOS-085601) quetiapine (HOS-086150) busulfan (HOS-115553) reboxetine (HOS-132863) alprazolam (HOS-086171) vinblastine (HOS-086220) risperidone (HOS-086280) vincristine (HOS-086219) imatinib (HOS-110212) docetaxel (HOS-084505) saquinavir (HOS-084522) bortezomib (HOS-110227) pimozide (HOS-085600) cabazitaxel (HOS-124028) buspirone (HOS-086325) paclitaxel (HOS-087959) haloperidol (HOS-085602) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 143b60c2365c220e7ae1ab4873f027ce623544d65995b03a1aab29b618d47f97 · Zeichen 15667–21466 im Abschnitt

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22

HOS-134523 · Präparat HOS-097580

Midazolam (oral) Triazolam Darunavir co-administered with low dose ritonavir is contraindicated with triazolam or oral midazolam (see section 4.3). TREATMENT FOR PREMATURE EJACULATION Dapoxetine Not studied. Co-administration of boosted darunavir with dapoxetine is contraindicated.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) triazolam (HOS-086168) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 4af993c90fa7ea3166cb29d5c6d3987a32184d9a125a8199877b44395874bd7f · Zeichen 68707–69407 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.